646 related articles for article (PubMed ID: 26966791)
1. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.
Hodge JA; Kawabata TT; Krishnaswami S; Clark JD; Telliez JB; Dowty ME; Menon S; Lamba M; Zwillich S
Clin Exp Rheumatol; 2016; 34(2):318-28. PubMed ID: 26966791
[TBL] [Abstract][Full Text] [Related]
2. Tofacitinib Suppresses Several JAK-STAT Pathways in Rheumatoid Arthritis
Palmroth M; Kuuliala K; Peltomaa R; Virtanen A; Kuuliala A; Kurttila A; Kinnunen A; Leirisalo-Repo M; Silvennoinen O; Isomäki P
Front Immunol; 2021; 12():738481. PubMed ID: 34630419
[TBL] [Abstract][Full Text] [Related]
3. Update on Janus kinase antagonists in inflammatory bowel disease.
Boland BS; Sandborn WJ; Chang JT
Gastroenterol Clin North Am; 2014 Sep; 43(3):603-17. PubMed ID: 25110261
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice.
Llop-Guevara A; Porras M; Cendón C; Di Ceglie I; Siracusa F; Madarena F; Rinotas V; Gómez L; van Lent PL; Douni E; Chang HD; Kamradt T; Román J
Arthritis Res Ther; 2015 Dec; 17():356. PubMed ID: 26653844
[TBL] [Abstract][Full Text] [Related]
5. Tofacitinib and peficitinib inhibitors of Janus kinase for autoimmune disease treatment: a quantum biochemistry approach.
Amaral JL; Lucredi NC; França VLB; Santos SJM; Maia FF; Morais PA; Souza PFN; Comar JF; Freire VN
Phys Chem Chem Phys; 2024 May; 26(17):13420-13431. PubMed ID: 38647171
[TBL] [Abstract][Full Text] [Related]
6. Monocyte-Derived Dendritic Cell Differentiation in Inflammatory Arthritis Is Regulated by the JAK/STAT Axis via NADPH Oxidase Regulation.
Marzaioli V; Canavan M; Floudas A; Wade SC; Low C; Veale DJ; Fearon U
Front Immunol; 2020; 11():1406. PubMed ID: 32733468
[TBL] [Abstract][Full Text] [Related]
7. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases.
T Virtanen A; Haikarainen T; Raivola J; Silvennoinen O
BioDrugs; 2019 Feb; 33(1):15-32. PubMed ID: 30701418
[TBL] [Abstract][Full Text] [Related]
8. JAK/STAT inhibition modifies the ILC1 immune response in patients with rheumatoid arthritis.
Lo Pizzo M; La Barbera L; Rizzo C; Mohammadnezhad L; Camarda F; Ciccia F; Guggino G
Clin Exp Rheumatol; 2024 Mar; 42(3):593-600. PubMed ID: 37812490
[TBL] [Abstract][Full Text] [Related]
9. Revealing the changes in signaling pathways caused by tofacitinib in patients with rheumatoid arthritis through RNA sequencing and the correlation with clinical parameters.
Lu F; Chen Q; Qi X; Cong M; Dai X; Liu H; Li Y
Clin Rheumatol; 2024 May; 43(5):1479-1489. PubMed ID: 38492091
[TBL] [Abstract][Full Text] [Related]
10. Advanced nanomedicine approach of JAK inhibitors: supporting treatment of rheumatoid arthritis.
Rani R; Raina N; Kumar A; Gupta PK; Gupta M
Nanomedicine (Lond); 2024 Feb; 19(4):277-280. PubMed ID: 38214205
[No Abstract] [Full Text] [Related]
11. Current status of immunological therapies for rheumatoid arthritis with a focus on antigen-specific therapeutic vaccines.
Zimmerman DH; Szekanecz Z; Markovics A; Rosenthal KS; Carambula RE; Mikecz K
Front Immunol; 2024; 15():1334281. PubMed ID: 38510240
[TBL] [Abstract][Full Text] [Related]
12. Reprint of "Residual pain in rheumatoid arthritis: Is it a real problem?".
Sarzi-Puttini P; Zen M; Arru F; Giorgi V; Choy EA
Autoimmun Rev; 2024 Jan; 23(1):103516. PubMed ID: 38272434
[TBL] [Abstract][Full Text] [Related]
13. The roles of HDAC with IMPDH and mTOR with JAK as future targets in the treatment of rheumatoid arthritis with combination therapy.
Mane RR; Kale PP
J Complement Integr Med; 2023 Dec; 20(4):689-706. PubMed ID: 36409592
[TBL] [Abstract][Full Text] [Related]
14. Novel Targeted Therapies for Rheumatoid Arthritis Based on Intracellular Signalling and Immunometabolic Changes: A Narrative Review.
Rahmati M; Kwesiga MP; Lou J; Tan AL; McDermott MF
Front Biosci (Landmark Ed); 2024 Jan; 29(1):42. PubMed ID: 38287839
[TBL] [Abstract][Full Text] [Related]
15. Tofacitinib in dermatology: a potential opportunity for topical applicability through novel drug-delivery systems.
Mahajan A; Sharma G; Thakur A; Singh B; Mehta H; Mittal N; Dogra S; Katare OP
Nanomedicine (Lond); 2024 Jan; 19(1):79-101. PubMed ID: 38197372
[TBL] [Abstract][Full Text] [Related]
16. Cell signalling in macrophages, the principal innate immune effector cells of rheumatoid arthritis.
Drexler SK; Kong PL; Wales J; Foxwell BM
Arthritis Res Ther; 2008; 10(5):216. PubMed ID: 18947379
[TBL] [Abstract][Full Text] [Related]
17. Case report: Occult
Deng C; Chiu KH; Lou N; Xing F
Front Med (Lausanne); 2023; 10():1322993. PubMed ID: 38264038
[TBL] [Abstract][Full Text] [Related]
18. Janus kinase inhibitors for rheumatoid arthritis.
Yamaoka K
Curr Opin Chem Biol; 2016 Jun; 32():29-33. PubMed ID: 26994322
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Fleischmann R; Mysler E; Hall S; Kivitz AJ; Moots RJ; Luo Z; DeMasi R; Soma K; Zhang R; Takiya L; Tatulych S; Mojcik C; Krishnaswami S; Menon S; Smolen JS;
Lancet; 2017 Jul; 390(10093):457-468. PubMed ID: 28629665
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
Cohen SB; Tanaka Y; Mariette X; Curtis JR; Lee EB; Nash P; Winthrop KL; Charles-Schoeman C; Thirunavukkarasu K; DeMasi R; Geier J; Kwok K; Wang L; Riese R; Wollenhaupt J
Ann Rheum Dis; 2017 Jul; 76(7):1253-1262. PubMed ID: 28143815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
